Skip to main content
Fig. 4 | BMC Complementary and Alternative Medicine

Fig. 4

From: Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids

Fig. 4

Anti-HSV-2 activity of the T. chebula extract, chebulagic acid, chebulinic acid and acyclovir in post-infection plaque reduction assay. Vero cells growing as monolayer in 24-well culture plate were infected with HSV-2 (100 PFU/well) followed by 1% low melting point agarose overlay medium containing varying concentration of the 50% ethanolic extract of T. chebula, chebulagic acid, chebulinic acid and acyclovir. After 48 h incubation, plates were processed to assess the number of plaques as described in Methods. The Y-axis represents percent inhibition in the number of plaques with respect to the vehicle treated virus control group and X-axis the concentration of the test extract/compounds. Each bar represents mean ± SEM of the three independent experiments performed in duplicate. Various panels are a extract of T. chebula, b chebulagic acid, c chebulinic acid and d acyclovir. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001 respectively between treated and vehicle control at tested concentration of the extract/compound

Back to article page